Past, imminent and future human medical countermeasures for anthrax

Journal of Applied Microbiology

Volumn 101, Issue 3, 2006, Pages 594-606

  Baillie, L W J ^a  

^a UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

Author keywords

Bacillus; Disease; Disease processes; Infection; Microbial structure; Therapeutics; Vaccines

Indexed keywords

BACTERIOLOGY; KNOWLEDGE BASED SYSTEMS; NEEDLES; VACCINES;

BACILLUS ANTHRACIS; DISEASE PROCESS; INFECTION; MEDICAL COUNTERMEASURES; MICROBIAL STRUCTURES; PROTECTIVE ANTIGENS; RESISTANT STRAINS; SECOND GENERATION; THERAPEUTIC; VACCINE DEVELOPMENT;

DISEASES;

ADJUVANT; ALUMINUM POTASSIUM SULFATE; AMOXICILLIN; ANTHRAX IMMUNOGLOBULIN; ANTHRAX TOXIN; ANTHRAX VACCINE; ANTIBIOTIC AGENT; ANTITOXIN; BETA LACTAM ANTIBIOTIC; CELL SURFACE RECEPTOR; CHLORAMPHENICOL; CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NEOARSPHENAMINE; PENICILLIN G; PROTECTIVE ANTIGEN; PROTEIN SUBUNIT; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; STREPTOMYCIN; SULFONAMIDE; TETRACYCLINE; TOXIN ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AIR TEMPERATURE; ANTHRAX; ANTIBIOTICS; BACTERIUM; MEDICAL GEOGRAPHY; TOXICITY; VACCINE;

ANIMAL DISEASE; ANTHRAX; ARTHRALGIA; BACILLUS ANTHRACIS; BACTERIAL SPORE; BACTERIAL VIRULENCE; BIOLOGICAL WARFARE; CONFERENCE PAPER; DRUG COST; DRUG SCREENING; FEVER; HUMAN; INFORMATION RETRIEVAL; INJECTION SITE SWELLING; MALAISE; MASS IMMUNIZATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRURITUS; RASH; SERUM; SERUM SICKNESS; VACCINATION; VACCINE PRODUCTION;

NEW MEXICO; NORTH AMERICA; SANTA FE [NEW MEXICO]; UNITED STATES;

ANIMALIA; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS);

EID: 33747114937     PISSN: 13645072     EISSN: 13652672     Source Type: Journal    
DOI: 10.1111/j.1365-2672.2006.03112.x     Document Type: Conference Paper

References (110)

1. Abramova, F.A., Grinberg, L.M., Yampolskaya, O.V. and Walker, D.H. (1993) Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. PNAS 90, 2291-2294.
2. Athamna, A., Athamna, M., Abu-Rashed, N., Medlej, B., Bast, D.J. and Rubinstein, E. (2004) Selection of Bacillus anthracis isolates resistant to antibiotics. J Antimicrob Chemother 54, 424-428.
3. Baillie, L.W.J. (2000) Bacillus anthracis. In Encyclopaedia of Food Microbiology ed. Batt, C.A., Robinson, R.K. and Patel, P.D. Vol. 1 pp. 129-135. London: Academic Press.
4. Baillie, L. (2001) The development of new vaccines against Bacillus anthracis. J Appl Microbiol 91, 609-613.
5. Baillie, L.W.J. and Read, T.D. (2001) Bacillus anthracis, a bug with attitude! Curr Opin Microbiol 4, 78-81.
6. Baillie, L., Hebdon, R., Flick-Smith, H. and Williamson, D. (2003) Characterisation of the immune response to the UK human anthrax vaccine. FEMS Immunol Med Microbiol 36, 83-86.
7. Baillie, L., Townend, T., Walker, N., Eriksson, U. and Williamson, D. (2004) Characterization of the human immune response to the UK anthrax vaccine. FEMS Immunol Med Microbiol 42, 267-270.
8. Baillie, L., Hibbs, S., Tsai, P., Cao, G.L. and Rosen, G.M. (2005) Role of superoxide in the germination of Bacillus anthracis endospores. FEMS Microbiol Lett 245, 33-38.
9. Barnes, J.M. (1947) The development of anthrax following the administration of spores by inhalation. Br J Exp Pathol 28, 385-394.
10. Beedham, R.J., Turnbull, P.C.B. and Williamson, E.D. (2001) Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 19, 4409-4416.
11. Bhan, M.K., Bahl, R. and Bhatnagar, S. (2005) Typhoid and paratyphoid fever. Lancet 366, 749-762.
12. Boyaka, P.N., Tafaro, A., Fischer, R., Leppla, S.H., Fujihashi, K. and McGhee, J.R. (2003) Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 170, 5636-5643.
13. Bradley, K.A., Mogridge, J., Mourez, M., Collier, R.J. and Young, J.A. (2001) Identification of the cellular receptor for anthrax toxin. Nature 414, 225-229.
14. Brook, I., Elliott, T.B., Pryor, H.I. 2nd, Sautter, T.E., Gnade, B.T., Thakar, J.H. and Knudson, G.B. (2001) In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents 18, 559-562.
15. Brossier, F., Levy, M., Landier, A., Lafaye, P. and Mock, M. (2004) Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect Immun 72, 6313-6317.
16. Casadevall, A. (2002) Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis 8, 833-841.
17. Cote, C.K., Rossi, C.A., Kang, A.S., Morrow, P.R., Lee, J.S. and Welkos, S.L. (2005) The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microb Pathog 38, 209-225.
18. Dixon, T.C., Melselson, M., Guillemin, J. and Hanna, P.C. (1999) Anthrax. N Engl J Med 341, 815-826.
19. Dong, S.L. (1990) Progress in the control and research of anthrax in China. Proceedings of the International Workshop on Anthrax, Winchester, UK, 11-13 April 1989. Sal Med Bull 68, 104-105.
20. Donganay, M. (1990) Human anthrax in Sivas, Turkey. Proceedings of the International Workshop on Anthrax, Winchester, UK, 11-13 April 1989. Sal Med Bull 68, 131.
21. Donnelly, J.J., Ulmer, J.B. and Liu, M.A. (1998) DNA vaccines. Dev Biol Stand 95, 43-53.
22. Duesbery, N.S., Webb, C.P., Leppla, S.H., Gorodon, V.M., Klimpel, K.R., Copeland, T.D., Ahn, N.G., Oskarsson, M.K. et al. (1998) Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280, 734-737.
23. Duguid, J.P., Marmian, B.P. and Swain, R.H.A. (1978) In Medical Microbiology, XIII edn ed. Mackie and McCartney pp. 346-360. Edinburgh: Churchill Livingstone.
24. Enstone, J.E., Wale, M.C., Nguyen-Van-Tam, J.S. and Pearson, J.C. (2003) Adverse medical events in British service personnel following anthrax vaccination. Vaccine 21, 1348-1354.
25. Etienne-Toumelin, I., Sirard, J.-C., Duflot, E., Mock, M. and Fouet, A. (1995) Characterisation of the Bacillus anthracis S-layer: cloning and sequencing of the structural gene. J Bacteriol 177, 614-620.
26. Expert Consultation on Monoclonal Antibodies for Anthrax rPA (2003) NIAID Biodefense: For Researchers: http://www.niaid.nih.gov/biodefense.
27. Ezzell, J.W. and Abshire, T.G. (1992) Serum protease cleavage of Bacillus anthracis protective antigen. J Gen Microbiol 138, 543-549.
28. Ezzell, J.W. and Abshire, T.G. (1996) Encapsulation of Bacillus anthracis spores and spore identification. Sal Med Bull 87, 42-43.
29. Ezzell, J.W. and Welkos, S.L. (1999) The capsule of Bacillus anthracis, a review. J Appl Microbiol 87, 250.
30. Fellows, P.F. (1996) A survey of worldwide strains of Bacillus anthracis. Sal Med Bull 87, 31-34.
31. Flick-Smith, H.C., Eyles, J.E., Hebdon, R., Waters, E.L., Beedham, R.J., Stagg, T.J., Miller, J., Alpar, H.O. et al. (2002) Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect Immun 70, 2022-2028.
32. Food and Drug Administration (2002) New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. 21CFR 314 and 601. U.S. Food and Drug Administration. Rockville, MD: Department of Health and Human Services.
33. Fouet, A., Mesnage, S., Tosi-Couture, E., Gounon, P. and Mock, M. (1999) Bacillus anthracis surface: capsule and S-layer. J Appl Microbiol 87, 251-255.
34. Friedlander, A.M., Welkos, S.L. and Ivins, B.E. (2002) Anthrax vaccines. Curr Top Microbiol Immunol 271, 33-60.
35. Friedlander, A.M., Welkos, S.L., Pitt, M.L.M., Ezzell, J.W., Worsham, P.L., Rose, K.J., Ivins, B.E., Lowe, J.R. et al. (1993) Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 167, 1239-1242.
36. Fujikura, T. (1990) Current occurrence of anthrax in man and animals. Proceedings of the International Workshop on Anthrax, Winchester, UK, 11-13 April 1989. Sal Med Bull 68, 1-2.
37. Galloway, D.R. and Baillie, L. (2004) DNA vaccines against anthrax. Expert Opin Biol Ther 4, 1661-1667.
38. Garmory, H.S., Brown, K.A. and Titball, R.W. (2002) Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev 26, 339-353.
39. Garmory, H.S., Titball, R.W., Griffin, K.F., Hahn, U., Bohm, R. and Beyer, W. (2003) Salmonella enterica serovar typhimurium expressing a chromosomally integrated copy of the Bacillus anthracis protective antigen gene protects mice against an anthrax spore challenge. Infect Immun 71, 3831-3836.
40. Gaur, R., Gupta, P.K., Banerjea, A.C. and Singh, Y. (2002) Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin. Vaccine 20, 2836-2839.
41. Gold, H. (1967) Treatment of anthrax. Fed Proc 26, 1563-1568.
42. Guidi-Rontani, C., Levy, M., Ohayon, H. and Mock, M. (2001) Fate of germinated Bacillus anthracis spores in primary murine macrophages. Mol Microbiol 42, 931-938.
43. Guidi-Rontani, C., Weber-Levy, M., Labruyere, E. and Mock, M. (1999a) Germination of Bacillus anthracis spores within aveolar macrophages. Mol Microbiol 31, 9-17.
44. Guidi-Rontani, C., Pereira, Y., Ruffie, S., Sirard, J-C., Weber-Levy, M. and Mock, M. (1999b) identification and characterisation of a germination operon on the virulence plasmid pXO1 of Bacillus anthracis. Mol Microbiol 33, 407-414.
45. Hahn, U.K., Boehm, R. and Beyer, W. (2005) DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components. Vaccine 24, 4569-4571.
46. Hanna, P.C. (1997) Anthrax pathogenesis and host response. Curr Top Microbiol Immunol 225, 13-35.
47. Hanna, P.C. and Ireland, J.A. (1999) Understanding Bacillus anthracis pathogenesis. Trends Microbiol 5, 180-182.
48. Henderson, D.W., Peacock, S. and Belton, F.C. (1956) Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg 54, 28-36.
49. Hermanson, G.V., Whitlow, S., Parker, K., Tonsky, D., Rusalov, M., Ferrari, P., Lalor, M., Komai, R. et al. (2004) A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. PNAS 101, 13601-13606.
50. Hoffmaster, A.R. and Koehler, T.M. (1999) Control of virulence gene expression in Bacillus anthracis. J Appl Microbiol 87, 279-281.
51. Hoffmaster, A.R., Ravel, J., Rasko, D.A., Chapman, G.D., Chute, M.D., Marston, C.K., De, B.K., Sacchi, C.T. et al. (2004) Identification of anthrax toxin genes in a Bacillus cereus associated with an illness resembling inhalation anthrax. PNAS 101, 8449-8454.
52. Hull, A.K., Criscuolo, C.J., Mett, V., Groen, H., Steeman, W., Westra, H., Chapman, G., Legutki, B. et al. (2005) Human-derived, plant-produced monoclonal antibody for the treatment of anthrax. Vaccine 23, 2082-2086.
53. Ivanovics, G. and Bruckner, V. (1937) Chemische und immunologische studien uber den mechanismus der milzbrandinfecktion und immunitat die chemische struktur der kapselsubstanz des milzbrandbazillus und der serolisch identischen spezifichen substanz des bacillus mesentericus. Z Immunitaetsforsch. Exp Ther 90, 304.
54. Jackson, R. (2000) Serum sickness. J Cutan Med Surg 4, 223-225.
55. Jernigan, D.B., Raghunathan, P.L., Bell, B.P., Brechner, R., Bresnitz, E.A., Butler, J.C., Cetron, M., Cohen, M. et al. (2002) Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 8, 1019-1028.
56. Kang, T.J., Fenton, M.J., Weiner, M.A., Hibbs, S., Basu, S., Baillie, L. and Cross, A.S. (2005) Murine macrophages kill the vegetative form of Bacillus anthracis. Infect Immun 73, 7495-7501.
57. Keim, P., Smith, K.L., Keys, C., Takahashi, H., Kurata, T. and Kaufmann, A. (2001) Molecular investigation of the Aum Shinrikyo anthrax release in Kameido, Japan. J Clin Microbiol 39, 4566-4567.
58. Keim, P., Price, L.B., Klevystka, A.M., Smith, K.L., Schupp, J.M., Okinaka, R., Jackson, P.J. and Hugh-Jones, M.E. (2000) Multiple-locus variable number tandem repeat analysis reveals genetic relationships with Bacillus anthracis. J Bacteriol 182, 2928-2936.
59. Kenney, R.T., Yu, J., Guebre-Xabier, M., Frech, S.A., Lambert, A., Heller, B.A., Ellingsworth, L.R., Eyles, J.E. et al. (2004) Induction of protective immunity against lethal anthrax challenge with a patch. J Infect Dis 190, 774-782.
60. Kew, O.M., Sutter, R.W., de Gourville, E.M., Dowdle, W.R. and Pallansch, M.A. (2005) Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 59, 587-635.
61. Knight, J. (2001) Delivering death in the mail. Nature 414, 837-838.
62. Knop, A.G. and Abalakin, V.A. (1986) Anthrax (Siberian Plague). In Epidemic Process as a Socio-ecological System. Handbook of Scientific Works. pp. 100-109. Moscow: Central Scientific Research Institute of Epidemiology.
63. Koya, V., Moayeri, M., Leppla, S.H. and Daniell, H. (2005) Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge. Infect Immun 73, 8266-8274.
64. Kozel, T.R., Murphy, W.J., Brandt, S., Blazar, B.R., Lovchik, J.A., Thorkildson, P., Percival, A. and Lyons, C.R. (2004) mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. PNAS 101, 5042-5047.
65. Leppla, S.H. (1991) The anthrax toxin complex. In Source Book of Bacterial Toxins ed. Alouf, J.E. and Freer, J.H. pp. 277-302. London: Academic Press.
66. Lightfoot, N.F., Scott, R.J.D. and Turnbull, P.C.B. (1990) Antimicrobial susceptibility of Bacillus anthracis. Proceedings of the International Workshop on Anthrax, Winchester, UK, 11-13 April 1989. Sal Med Bull 68, 95-98.
67. Little, S.F. and Ivins, B.E. (1999) Molecular pathogenesis of Bacillus anthracis infection. Microbes Infect 2, 131-139.
68. Little, S.F., Ivins, B.E., Fellows, P.F., Pitt, M.L., Norris, S.L. and Andrews, G.P. (2004) Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22, 422-430.
69. Liu, H., Bergman, N.H., Thomason, B., Shallom, S., Hazen, A., Crossno, J., Rasko, D.A., Ravel, J. et al. (2004) Formation and composition of the Bacillus anthracis endospore. J Bacteriol 186, 164-178.
70. Makino, S., Uchida, I., Terakado, N., Sasakawa, C. and Yoshikawa, M. (1989) Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J Bacteriol 171, 722-730.
71. Mignot, T., Mock, M., Robichon, D., Landier, A., Lereclus, D. and Fouet, A. (2001) The incompatibility between the PlcR- and AtxA-controlled regulons may have selected a nonsense mutation in Bacillus anthracis. Mol Microbiol 42, 1189-1198.
72. Moayeri, M. and Leppla, S.H. (2004) The roles of anthrax toxin in pathogenesis. Curr Opin Microbiol 7, 19-24.
73. O'Brien, J., Friedlander, A., Dreier, T., Ezzell, J. and Leppla, S. (1985) Effects of anthrax toxin components on human neutrophils. Infect Immun 47, 306-310.
74. Panchal, R.G., Halverson, K.M., Ribot, W., Lane, D., Kenny, T., Abshire, T.G., Ezzell, J.W., Hoover, T.A. et al. (2005) Purified Bacillus anthracis lethal toxin complex formed in vitro and during infection exhibits functional and biological activity. J Biol Chem 280, 10834-10839.
75. Partidos, C. (2003) Antigens onto bare skin: a 'painless' paradigm shift in vaccine delivery. Expert Opin Biol Ther 3, 895-902.
76. Pasteur, L. (1881) De l'attenuation des virus et de leur retour a la virulence. CR Acad Sci Agric Bulg 92, 429-435.
77. Pellizzari, R., Guidi-Rontani, C., Vitale, G., Mock, M. and Montecucco, C. (1999) Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFN gamma release of NO and TNF alpha. FEBS Lett 462, 199-204.
78. Petosa, C., Collier, R.J., Klimpel, K.R., Leppla, S.H. and Liddington, R.C. (1997) Crystal structure of the anthrax toxin protective antigen. Nature 385, 833-838.
79. Phipps, A.J., Premanandan, C., Barnewall, R.E. and Lairmore, M.D. (2004) Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol Mol Biol Rev 68, 617-629.
80. Pittman, P.R., Leitman, S.F., Oro, J.G., Norris, S.L., Marano, N.M., Ranadive, M.V., Sink, B.S. and McKee, K.T. Jr. (2005) Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. Clin Diagn Lab Immunol 12, 713-721.
81. Pittman, P.R., Kim-Ahn, G., Pifat, D.Y., Coonan, K., Gibbs, P., Little, S., Pace-Templeton, J.G., Myers, R. et al. (2002) Anthrax vaccine: immunogenicity and safety of a dosereduction, route-change comparison study in humans. Vaccine 20, 1412-1420.
82. Pomerantsev, A.P., Staritsin, N.A., Mockov, Yu.V. and Marinin, L.I. (1997) Expression of cereolysine AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine 15, 1846-1850.
83. Price, B.M., Liner, A.L., Park, S., Leppla, S.H., Mateczun, A. and Galloway, D.R. (2001) Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun 69, 4509-4515.
84. Priest, F.G., Barker, M., Baillie, L.W., Holmes, E.C. and Maiden, M.C. (2004) Population structure and evolution of the Bacillus cereus group. J Bacteriol 186, 7959-7970.
85. Pugh, A.O. and Davies, J.C.A. (1990) Human anthrax in Zimbabwe. Proceedings of the International Workshop on Anthrax, Winchester, UK, 11-13 April 1989. Sal Med Bull 68, 32-33.
86. Quinn, C.P., Dull, P.M., Semenova, V., Li, H., Crotty, S., Taylor, T.H., Steward-Clark, E., Stamey, K.L. et al. (2004) Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis 190, 1228-1236.
87. Raines, K.W., Kang, T.J., Hibbs, S., Cao, G.L., Weaver, J., Tsai, P., Baillie, L., Cross, A.S. et al. (2006) Importance of nitric oxide synthase in the control of infection by Bacillus anthracis. Infect Immun 74, 2268-2267.
88. Rainey, G.J. and Young, J.A. (2004) Antitoxins: novel strategies to target agents of bioterrorism. Nat Rev Microbiol 2, 721-726.
89. Read, T.D., Peterson, S.N., Tourasse, N., Baillie, L.W., Paulsen, I.T., Nelson, K.E., Tettelin, H., Fouts, D.E. et al. (2003) The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria. Nature 423, 81-86.
90. Redmond, C., Baillie, L.W., Hibbs, S., Moir, A.J. and Moir, A. (2004) Identification of proteins in the exosporium of Bacillus anthracis. Microbiology 150, 355-363.
91. Rosovitz, M.J., Schuck, P., Varughese, M., Chopra, A.P., Mehra, V., Singh, Y., McGinnis, L.M. and Leppla, S.H. (2003) Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J Biol Chem 278, 30936-30944.
92. Schneerson, R., Kubler-Kielb, J., Liu, T.Y., Dai, Z.D., Leppla, S.H., Yergey, A., Backlund, P., Shiloach, J. et al. (2003) Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. PNAS 100, 8945-8950.
93. Shepard, C.W., Soriano-Gabarro, M., Zell, E.R., Hayslett, J., Lukacs, S., Goldstein, S., Factor, S., Jones, J. et al. (2002) CDC adverse events working group. Antimicrobial post exposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 8, 1124-1132.
94. Sirard, J.C., Weber, M., Duflot, E., Popoff, M.R. and Mock, M. (1997) A recombinant Bacillus anthracis strain producing the Clostridium perfringens Ib component induces protection against iota toxin. Infect Immun 65, 2029-2033.
95. Smith, H. and Keppie, J. (1954) Observations on experimental anthrax; demonstration of a specific lethal factor produced in vivo by Bacillus anthracis. Nature 173, 869-870.
96. Stepanov, A.V., Marinin, L.I., Pomerantsev, A.P. and Staritsin, N.A. (1996) Development of novel vaccines against anthrax in man. J Biotechnol 44, 155-160.
97. Stepanov, A.S., Mikshis, N.I., Eremin, S.A. and Bolotnikova, M.F. (1999) Contribution of determinants located in Bacillus anthracis chromosomes, in pathogenic properties of the pathogen. Mol Gen Mikrobiol Virusol 1, 20-23.
98. Sterne, M. (1967) Distribution and economic importance of anthrax. Fed Proc 26, 1493-1495.
99. Stoger, E., Ma, J.K., Fischer, R. and Christou, P. (2005) Sowing the seeds of success: pharmaceutical proteins from plants. Curr Opin Biotechnol 16, 167-173.
100. Tacket, C.O., Mason, H.S., Losonsky, G., Estes, M.K., Levine, M.M. and Arntzen, C.J. (2000) Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 182, 302-305.
101. Turnbull, P.C.B. (1996) Anthrax is alive and well. PHLS Microbiol Dig 9, 103-106.
102. Turnbull, P.C.B. (2000) Current status of immunisation against anthrax: old vaccines may be here to stay for a while. Curr Opin Infect Dis 13, 113-120.
103. Uchida, I., Makino, S., Sasakawa, C., Yoshikawa, C., Sugimoto, C. and Terakado, N. (1993) Identification of a novel gene, dep, associated with depolymerization of the capsular polymer in Bacillus anthracis. Mol Microbiol 9, 487-496.
104. Wasserman, G.M., Grabenstein, J.D., Pittman, P.R., Rubertone, M.V., Gibbs, P.P., Wang, L.Z. and Golder, J.G. (2003) Analysis of adverse events after anthrax immunization in US Army medical personnel. J Occup Environ Med 45, 222-233.
105. Williamson, E.D., Hodgson, I., Walker, N.J., Topping, A.W., Duchars, M.G., Mott, J.M., Estep, J., Lebutt, C. et al. (2005) Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect Immun 73, 5978-5987.
106. Wright, G.G. and Mandell, G.L. (1986) Anthrax toxin blocks priming of neutrophils by lipo-polysaccharide and by muramyl dipeptide. J Exp Med 164, 1700-1709.
107. Wright, G.G., Read, P.W. and Mandell, G.I. (1988) Lipopolysaccharide releases a priming substance from platelets that augments the oxidative response of polymorphonuclear neutrophils to chemotactic peptide. J Infect Dis 157, 690-696.
108. Zeger, N.D., Kluter, E., van der Stap, H., van Dura, E., van Dalen, P., Shaw, M. and Baillie, L.W.J. (1999) Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: towards the development of an oral vaccine against anthrax. J Appl Microbiol 87, 309-314.
109. Zilinska, R.A. (1997) Iraq's biological weapons. JAMA 278, 418-424.
110. Zwick, M.E., Mcafee, F., Cutler, D.J., Read, T.D., Ravel, J., Bowman, G.R., Galloway, D.R. and Mateczun, A. (2005) Microarray-based resequencing of multiple Bacillus anthracis isolates. Genome Biol 6, R10.